Hostname: page-component-586b7cd67f-t7czq Total loading time: 0 Render date: 2024-11-22T07:04:54.208Z Has data issue: false hasContentIssue false
  • English
  • Français

The Myth of Elevated Serum Creatine Phosphokinase Level and Neuroleptic Malignant Syndrome

Published online by Cambridge University Press:  02 January 2018

Adityanjee
Adityanjee*
Affiliation:
Department of Psychiatry, The Maudsley Hospital, Denmark Hill, London SE5 8AZ
Get access Rights & Permissions [Opens in a new window]

Extract

The 1980s witnessed the honeymoon between American psychiatry and an enigmatic and mysterious drug complication called neuroleptic malignant syndrome (NMS). I fear that the 1990s are witnessing the same in British psychiatry. Gone is the era when case reports in British literature described the syndrome without identifying it by name (Allan & White, 1972; Moyes, 1973), ostensibly owing to lack of awareness. Probably, no one had bothered to read the original description in the French-language literature (Delay et al, 1960). The pendulum has now swung to the other extreme. Every known drug-related complication is being labelled NMS. In the US, Addonizio et al (1986) suggested a ridiculously high incidence figure of 12.2%. The same trend for overdiagnosis is seen in the recent case report by Dalkin & Lee (1990). The authors of this case report seem to have forgotten that NMS is an idiosyncratic adverse drug reaction which is dose-independent. There is no reason to label every neuroleptic overdose as NMS on grounds of raised creatine phosphokinase (CPK) level.

Type
Point of View
Information
The British Journal of Psychiatry , Volume 158 , Issue 5 , May 1991 , pp. 706 - 707
Copyright
Copyright © Royal College of Psychiatrists, 1991 

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Adityanjee, , Singh, S., Sinoh, G., et al (1988) Spectrum concept of neuroleptic malignant syndrome. British Journal of Psychiatry, 153, 107–111.Google Scholar
Addonizio, G., Susman, V. L. & Roth, S. D. (1986) Symptoms of neuroleptic malignant syndrome in 82 consecutive inpatients. American Journal of Psychiatry, 143, 1587–1590.Google ScholarPubMed
Allan, R. N. & White, H. C. (1972) Side effects of parental long–acting phenothiazines. British Medical Journal, i, 221.Google Scholar
Black, H. R., Quillich, H. & Gareleck, C. B. (1986) Racial differences in serum creatine kinase levels. American Journal of Medicine, 81, 479–487.Google Scholar
Cavanaugh, J. J. & Finlayson, R. E. (1984) Rhabdomyolysis due to acute dystonic reaction to antipsychotic drugs. Journal of Clinical Psychiatry, 45, 356–357.Google Scholar
Dalkin, T. & Lee, A. S. (1990) Carbamazepine and forme fruste of neuroleptic malignant syndrome. British Journal of Psychiatry, 157, 437–438.Google Scholar
Delay, J., Pichot, P. & Lemperiere, T. (1960) Un neuroleptique majeur non phenothiazine et non reserpinique, l'haloperidol, dans le traftement des psychoses. Annates Medico–Psychologiques, 118, 145–152.Google Scholar
Dreyfus, J. C., Schapira, G., Resnais, J., et al (1960) Le creatine-kinase serique dans le diagnostic de l'infarctus myocardique. Revue Francaise d'Etudes Cliniques et Biologiques, 5, 386–387.Google Scholar
Gabow, P. A., Kaehny, W. D. & Kelleher, S. P. (1982) The spectrum of rhabdomyolysis. Medicine, 61, 141–152.CrossRefGoogle ScholarPubMed
Galen, R. S. (1975) The enzyme detection of myocardial infarction. Human Pathology, 6, 141–155.Google Scholar
Goldberg, D. A. & Winfield, D. A. (1972) Diagnostic accuracy of serum enzyme essays for myocardial infarction in a general hospital population. British Heart Journal, 34, 597–604.Google Scholar
Grande, P., Christiansen, C. & Pedersen, A. (1978) Creatine kinase MB isoenzyme in diagnosis of acute myocardial infarction. Acta Medica Scandinavica, 623, 48–52.Google ScholarPubMed
Grande, P., Christiansen, C. & Pedersen, A. et al (1980) Optimal diagnosis in acute myocardial infarction. Circulation, 61, 723–728.Google Scholar
Johnson, S. B., Alvarez, W. A., & Freinhar, J. P. (1986) A case of massive rhabdomyolysis following molindone administration. Journal of Clinical Psychiatry, 47, 607–608.Google Scholar
Kellam, A. M. P. (1990) The (frequently) neuroleptic (potentially) malignant syndrome. British Journal of Psychiatry, 157, 169–173.Google Scholar
Levenson, J. L. (1985) Neuroleptic malignant syndrome. American Journal of Psychiatry, 142, 1137–1145.Google Scholar
Levenson, J. L. (1986) Reply to “Diagnosing and treating neuroleptic malignant syndrome”. American Journal of Psychiatry, 143, 675.Google Scholar
Lui, W. Y. (1979) Phenothiazine–induced dystonia associated with an increase in serum creatine phosphokinase. Archives of Diseases in Childhood, 54, 150–151.Google Scholar
Meltzer, H. Y., Eklum, L. & Moline, R. A. (1969) Serum–enzyme changes in newly admitted psychiatric patients. Archives of General Psychiatry, 21, 731–738.Google Scholar
Meltzer, H. Y., Kupfer, D. J., Wyatt, R., et al (1970) Sleep disturbance and serum CPK activity in acute psychosis. Archives of General Psychiatry, 71, 398–405.Google Scholar
Moyes, D. G. (1973) Malignant hyperpyrexia caused by trimeprazine. British Journal of Anaesthesia, 45, 1163–1164.Google Scholar
Pearlman, C., Wheadon, D. & Epstein, S. (1988) Creatine kinase elevation after neuroleptic treatment. American Journal of Psychiatry, 145, 1018–1019.Google Scholar
Ravi, S. D., Broge, G. F. & Roach, F. L. (1982) Neuroleptics, laryngeal–pharyngeal dystonia and acute renal failure. Journal of Clinical Psychiatry, 43, 300.Google Scholar
Sobel, B. E. & Shell, W. E. (1972) Serum enzyme determinations in the diagnosis and assessment of myocardial infarction. Circulation, 45, 471–482.CrossRefGoogle ScholarPubMed
Velamoor, V. R., Fernando, M. L. D. & Williamson, P. (1990) Incipient neuroleptic malignant syndrome. British Journal of Psychiatry, 156, 581–584.Google Scholar
Wagner, G. S. (1980) Optimal use of serum enzyme levels in the diagnosis of acute myocardial infarction. Archives of Internal Medicine, 140, 317–319.Google Scholar
Submit a response

eLetters

No eLetters have been published for this article.